| Mechanism | Selective elimination of senescent cells (senolytics) or modulation of their pro-inflammatory phenotype (senomorphics). |
| Key Compounds | Dasatinib, Quercetin, Fisetin, Piperlongumine, Navitoclax, FOXO4-DRI, Rapamycin, Metformin, Nicotinamide, Apigenin, Resveratrol. |
| Current Clinical Phase | Phase 1/2 trials for specific indications (IPF, DKD, AD, bone health); preclinical for osteoarthritis and sensory decline. |
| Level of Evidence | Moderate (human pilot trials), Low (preclinical/animal studies for some compounds). |
| Administration | Intermittent "hit-and-run" (senolytics) or continuous (senomorphics). |
Cellular senescence interventions encompass two primary therapeutic strategies: senolytics, which selectively eliminate senescent cells by disrupting their survival networks, and senomorphics, which suppress the pro-inflammatory Senescence-Associated Secretory Phenotype (SASP). Clinical trials with the combination of Dasatinib and Quercetin have successfully demonstrated target engagement, showing reduced tissue senescent cell markers ( and ) and decreased circulating SASP factors (such as IL-6 and MCP-1) in human patients. Intermittent dosing regimens (e.g., 2–3 consecutive days every few weeks) are utilized to clear senescent cells while minimizing off-target adverse effects and allowing normal tissue homeostasis.
Cellular senescence is a fundamental biological state of stable, irreversible cell cycle arrest triggered by cellular stressors, including DNA damage response (DDR) activation, telomere attrition, oncogene activation, and mechanical microenvironmental stress [[1], [2]]. While transient cellular senescence plays critical physiological roles during embryonic development and tissue wound healing, the chronic accumulation of senescent cells with age contributes to tissue degeneration and chronic inflammatory diseases.
Senescent cells remain highly metabolically active and secrete a potent cocktail of pro-inflammatory cytokines, chemokines, growth factors, and extracellular matrix-degrading metalloproteinases, collectively termed the Senescence-Associated Secretory Phenotype (SASP) [[2:1]]. Interventions targeting this process fall into two main categories:
STRESSORS
(DNA Damage, Mechanical Stiffness, Telomere Attrition)
│
▼
CELLULAR SENESCENCE
┌──────────┴──────────┐
▼ ▼
Apoptosis Resistance Harmful SASP
(SCAP Pathway Active) (IL-1β, IL-6, MMPs)
│ │
[SENOLYTICS] TARGETS [SENOMORPHICS] TARGETS
│ │
▼ ▼
Selective Apoptosis SASP Suppression
(Tissue Cleansing/Repair) (Inflammation Control)
Senescent cells rely on specialized survival networks—SCAPs—to resist the pro-apoptotic signals induced by their own intracellular damage. Senolytics act by transiently disabling these SCAP networks, allowing the senescent cell to undergo programmed cell death (apoptosis) [[3:1]].
Conversely, senomorphics work upstream of the secretory machinery. By inhibiting key nutrient and energy sensors (such as mTORC1), they suppress the translation and release of destructive SASP factors, effectively silencing the senescent cell's inflammatory signal and protecting the surrounding tissue microenvironment [[4:1]].
| Intervention | Target Population | Clinical Outcomes & Findings | Certainty | Study Type & Key Citations |
|---|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Idiopathic Pulmonary Fibrosis (IPF) | Improved physical function: 6-minute walk distance (+21.5m), gait speed (+0.1m/s), chair-stand time (-1.5s), and Short Physical Performance Battery (SPPB). No significant pulmonary function changes. | Moderate | Phase 1 Open-Label Pilot Trial (n=14) [5] |
| Dasatinib + Quercetin (D+Q) | Diabetic Kidney Disease (DKD) | Reduced senescent cell burden in adipose tissue (p16+ and p21+ cells, SA-β-gal activity) and decreased circulating SASP factors (IL-1α, IL-6, IL-8, MCP-1, MMP-9, MMP-12). | Moderate | Phase 1 Open-Label Trial (n=9) [6] |
| Dasatinib + Quercetin (D+Q) | Postmenopausal Women | Demonstrated safety and feasibility of intermittent dosing; established bone metabolic biomarker target engagement, though bone mineral density changes were not statistically significant. | Moderate | Phase 2 Randomized Controlled Trial (n=120) [7] |
| Dasatinib + Quercetin (D+Q) | Mild Alzheimer's Disease (AD) | Feasible and well-tolerated intermittent regimen; exploratory fluid biomarkers in CSF showed potential reduction in chemokine/SASP profiles. | Low | Phase 1 Feasibility Trial (SToMP-AD, n=5) [8] |
| Fisetin | Obese Men | Supplementation combined with exercise significantly decreased pro-inflammatory adipokines (asprosin, IL-6, TNF-α) and upregulated the pro-resolving lipid mediator Maresin-1. | Moderate | Phase 2 Randomized Controlled Trial [9] |
| Fisetin | Healthy Adults | Bioavailability study confirming that standard unformulated Fisetin is rapidly metabolized; a hybrid-hydrogel formulation achieved a 47-fold increase in plasma concentrations. | Moderate | Double-Blind Randomized Crossover Study (n=24) [10] |
| Piperlongumine (PL) | Osteoarthritis (OA) | Insufficient human clinical trial data. Selectively eliminates senescent meniscus cells and chondrocytes. In human ex vivo patient-derived OA joint tissues, PL clears senescent cells and enhances glycosaminoglycan (matrix) production. | Low (Preclinical / Ex Vivo) | ex vivo and in vivo animal studies [11] |
| Rapamycin + Nicotinamide (NAM) | Senescent Stem Cells (MSCs) | Insufficient human in vivo data. In ex vivo mesenchymal stem cells (MSCs) isolated from elderly donors, short-term combination treatment decreases p16/p21, total ROS, and restores osteogenic differentiation. | Low (Preclinical / Ex Vivo) | ex vivo human stem cell models [4:2] |
| Navitoclax (ABT-263) | Oncology / Healthy Humans | Insufficient healthy human data. Primary clinical trials are restricted to hematological oncological indications; senolytic use in healthy humans is limited due to severe thrombocytopenia risks. | Low | Preclinical & Oncological Feasibility |
| FOXO4-DRI Peptide | Healthy Humans | Insufficient human data. Action remains entirely preclinical; clinical efficacy and safety profiles in humans have not yet been evaluated. | Low | Preclinical |
| Metformin (AMPK activator) | Healthy Humans | Insufficient senomorphic-specific human data. Longevity and senomorphic benefits in non-diabetic humans are currently under investigation (e.g., TAME trial). | Low | Preclinical & In Vitro |
Certainty Grade Rubric:
Traditional understanding focused almost exclusively on biochemical and genotoxic triggers of cellular senescence. However, recent findings have established that mechanical stress from extracellular matrix (ECM) stiffening is a direct inducer of endothelial network senescence [[1:1]].
Sensory cell senescence represents a major component of age-related functional decline. In auditory systems, cellular senescence in auditory hair cells drives age-related hearing loss (presbycusis) [[12]].
In oncological contexts, cellular senescence acts as a double-edged sword. Chemotherapeutic and radiotherapeutic regimens induce senescence in tumor cells, known as Therapy-Induced Senescence (TIS) [[13]].
Potential Beneficiaries:
Who Should Avoid or Exercise Extreme Caution:
Interventions targeting cellular senescence utilize two distinct pharmacological strategies based on their mechanism of action: intermittent clearance for senolytics and continuous modulation for senomorphics.
Because senescent cells accumulate slowly over weeks to months, continuous dosing of senolytics is unnecessary and increases the risk of systemic side effects. Instead, clinical protocols employ an intermittent dosing strategy, clearing the senescent burden in brief cycles [[14:1]].
Unlike senolytics, senomorphics are administered continuously or on a sustained schedule to continuously suppress SASP production and promote cellular autophagy [[4:4]].
Red Flag Symptoms (Cease protocol and seek immediate evaluation):
Because senescent cell clearance is largely internal, tracking efficacy requires a multi-marker framework combining laboratory biomarkers with functional assessments [[6:2]].
DESIRED THERAPEUTIC GOAL
│
┌────────────────────┴────────────────────┐
▼ ▼
Direct Clearance of SnCs SASP Secretion Suppression
(Intermittent Senolytic) (Continuous Senomorphic)
│ │
┌───────────┴───────────┐ ├──────────────────────────┐
▼ ▼ ▼ ▼
Systemic Burden Joint Osteoarthritis Mesenchymal Stem Cells Metabolic Regulation
(D+Q or Fisetin) (Piperlongumine / PL) (Rapamycin + Nicotinamide) (Metformin)
│ │ │ │
Intermittent D+Q Local IA PL ex-vivo Short-term ex-vivo Continuous daily
2-3 days / month preclinical models pre-treatment phase clinical dosing
Senolytics are therapeutic agents designed to selectively eliminate senescent cells by triggering programmed cell death (apoptosis). Senomorphics do not kill senescent cells; instead, they suppress the expression and secretion of the harmful, pro-inflammatory Senescence-Associated Secretory Phenotype (SASP), reducing their toxic systemic effects.
Intermittent dosing (the "hit-and-run" approach) is utilized because senescent cells accumulate slowly over time and do not need daily clearance. Furthermore, transient senescent cells play essential physiological roles in wound healing and tissue remodeling. Avoiding daily suppression allows normal tissue repair to occur while preventing long-term drug toxicity.
While Fisetin acts as an antioxidant at low continuous doses, its senolytic effects are only achieved when it reaches high transient threshold concentrations in blood plasma. This requires specialized high-bioavailability formulations and an intermittent, high-dose pulsing regimen rather than standard daily antioxidant supplementation.
Increased extracellular matrix stiffness acts as a direct mechanical stressor that induces senescence in endothelial cells. This mechanical senescence is mediated by the activation of Notch signaling and occurs independently of biochemical inflammatory signals, demonstrating that the physical microenvironment directly shapes cell aging.
The content of this clinical deep dive was synthesized by evaluating scientific literature, systematic reviews, and peer-reviewed clinical trial data.
Song J, Rindone AN, Guan Y. Matrix Stiffness Induces Endothelial Network Senescence. Advanced Science. 2026. https://pubmed.ncbi.nlm.nih.gov/42389866/ ↩︎ ↩︎ ↩︎
Hussain A, Tatar M, Gong R. Molecular mechanisms and recent advances in cellular senescence. Cell & Bioscience. 2026. https://pubmed.ncbi.nlm.nih.gov/42286666/ ↩︎ ↩︎ ↩︎ ↩︎
Singh I, Singh AK. Senolytics as Modulators of Critical Signaling Pathways: a Promising Strategy to Combat Brain Aging and Neurodegenerative Disorders. Molecular Neurobiology. 2025. https://pubmed.ncbi.nlm.nih.gov/41351658/ ↩︎ ↩︎
Khorraminejad-Shirazi M, Sani M, Falamarzi K, et al. Rapamycin and nicotinamide treatment attenuates senescence-associated features in mesenchymal stromal cells isolated from elderly donors by modulating autophagy. Scientific Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/42380169/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30616998/ ↩︎ ↩︎ ↩︎
Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/31542391/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38956196/ ↩︎ ↩︎
Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37679434/ ↩︎
Alipour M, Saeidi A, Hejazi K, et al. The Effects of Interval Resistance-Aerobic Training and Fisetin Supplementation on Asprosin and Selected Adipokines in Obese Men: A Double-Blind Randomized Control Trial. Nutrients. 2026. https://pubmed.ncbi.nlm.nih.gov/41683255/ ↩︎ ↩︎ ↩︎
Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. Journal of Nutritional Science. 2022. https://pubmed.ncbi.nlm.nih.gov/36304817/ ↩︎ ↩︎ ↩︎ ↩︎
Endo K, Ozeki N, Koga H, et al. Piperlongumine attenuates knee osteoarthritis progression by eliminating senescent meniscus cells and chondrocytes. Biochemical and Biophysical Research Communications. 2026. https://pubmed.ncbi.nlm.nih.gov/42322814/ ↩︎ ↩︎ ↩︎
Li L, Xiao Y, Liu X, et al. AUF1 modulates cellular senescence in auditory hair cells by regulating the transcription and alternative splicing of immune response genes. Molecular Biology Reports. 2026. https://pubmed.ncbi.nlm.nih.gov/42189329/ ↩︎ ↩︎
Tomacinschii V, Casian A, Robu M. Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets. Current Cancer Drug Targets. 2026. https://pubmed.ncbi.nlm.nih.gov/42312503/ ↩︎ ↩︎
Wissler Gerdes EO, Misra A, Netto JME, et al. Strategies for late phase preclinical and early clinical trials of senolytics. Mechanisms of Ageing and Development. 2021. https://pubmed.ncbi.nlm.nih.gov/34699859/ ↩︎ ↩︎ ↩︎ ↩︎
Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. https://pubmed.ncbi.nlm.nih.gov/29988130/ ↩︎
Alameen AAM, Al-Kuraishy HM, Fawzy MN. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. https://pubmed.ncbi.nlm.nih.gov/42024235/ ↩︎
Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017. https://pubmed.ncbi.nlm.nih.gov/28340347/ ↩︎